Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
26.99
+0.59 (2.23%)
Nov 21, 2024, 1:24 PM EST - Market open
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CLDX stock have an average target of 64.83, with a low estimate of 37 and a high estimate of 90. The average target predicts an increase of 140.20% from the current stock price of 26.99.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CLDX stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +196.41% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +196.41% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +196.41% | Oct 28, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +159.36% | Oct 7, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $45 | Hold | Initiates | $45 | +66.73% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
5.60M
from 6.88M
Decreased by -18.63%
Revenue Next Year
3.72M
from 5.60M
Decreased by -33.62%
EPS This Year
-2.51
from -2.92
EPS Next Year
-3.21
from -2.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.9M | 12.6M | 11.8M | ||
| Avg | 5.6M | 3.7M | 3.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.7% | 125.0% | 216.3% | ||
| Avg | -18.6% | -33.6% | 3.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.34 | -2.58 | -2.32 | ||
| Avg | -2.51 | -3.21 | -3.83 | ||
| Low | -2.57 | -3.59 | -4.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.